The Relationship between Protoporphyrin IX and Platelet Count in the Protoporphyrias
Authors: Leaf Rebecca Karp , Jiang Paul Yanning , Goddu R. Jay , Tran Benny , Rebeiz Lina , Elmariah Sarina , Hodges Pamela G , Mead Jennifer , Trinidad John , Saberi Behnam , Fleming Mark D. , Ducamp Sarah , Anderson Karl , Dickey Amy 
Published: December 2023

Introduction: Erythropoietic protoporphyria and X-linked protoporphyria, collectively known as the protoporphyrias, are inherited disorders of heme biosynthesis characterized by the accumulation of protoporphyrin IX in the skin and other organs. Clinical manifestations include severe pain with exposure to sunlight, as well as liver disease in a subset of patients. Approximately half of patients with protoporphyria have mild microcytic anemia, which is not well understood but thought to be related either to decreased iron availability or to decreased heme biosynthesis. Several reports have described mild thrombocytopenia in patients with protoporphyria (Delaby et al., 2009, Wensink et al., 2022), although thrombocytosis would be expected with iron deficiency as low iron biases megakaryocyte-erythroid progenitors to the megakaryocyte lineage (Xavier-Ferrucio et al., 2019). We sought to further characterize the relationship between erythrocyte metal-free protoporphyrin IX (PPIX) levels, platelet count, and iron status in patients with protoporphyria.
Methods: We conducted a single-center cohort study of adults with protoporphyria treated at the Massachusetts General Hospital Porphyria Center from March 2021 through June 2023. Patient-level data across multiple time points were collected, including platelet count, ferritin, and alanine transaminase (ALT). Generalized Estimating Equation (GEE) models with an identity link and gaussian family distribution were performed to determine the association, accounting for within-participant associations.
Results: A total of 38 patients with protoporphyria were included in the analysis. The median PPIX level was 1169.5ug/dl (interquartile range [IQR] 729.50 - 2069.75, reference range &lt;20). The median platelet count was 208 x10 9/L (IQR, 171-243, reference range 150-400). Only 3 patients had a platelet count &lt;150 x10 9/L and none &lt;100 x10 9/L. A 1ug/dl increase in protoporphyrin level was associated with an 0.02 x10 9/L decrease in platelet count on average (p= &lt; 0.00001, Figure).
We next sought to evaluate whether the relationship between PPIX and platelet count was affected by iron status (assessed by ferritin) or liver disease (assessed by ALT). When adjusting for ferritin and ALT, the relationship between PPIX and platelet count remained statistically significant (p= &lt; 0.00001). When adjusting for PPIX and ferritin, an increase in platelets was associated with an increase in ALT (p=0.002), but there was no significant relationship between ferritin and PPIX when adjusting for the other variables in the model.
Conclusion: In this study of 38 patients with protoporphyria, higher levels of PPIX were associated with lower platelet counts. This association was independent of markers of iron status or hepatic dysfunction. Only 3 patients had thrombocytopenia, which was mild in all cases. Although increased PPIX was not associated with clinically significant thrombocytopenia, the reason for the relationship between PPIX and platelets in this patient population remains unclear. Considering the well-described risk of anemia in protoporphyria, there may exist some unknown effect on hematologic cells and their precursors, either due to the accumulation of PPIX or variants in heme biosynthetic enzymes. Understanding this fundamental biology may pave the way for further treatment targets in protoporphyria and other hematologic conditions.